Xiaoyu Zhu

Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial

Binghe Xu, Min Yan, Fei Ma et al. · The Lancet Oncology · 2021 · 372 citations

Capecitabine Versus Lapatinib, Breast Oncology, Medicine +8

Pyrotinib or Lapatinib Combined With Capecitabine in HER2–Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study

Fei Ma, Quchang Ouyang, Wěi Li et al. · Journal of Clinical Oncology · 2019 · 335 citations

Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial

Yi-Zhou Jiang, Yin Liu, Yi Xiao et al. · Cell Research · 2020 · 298 citations · Full text

Pyrotinib in <i>HER2</i>-Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study

Caicun Zhou, Xingya Li, Qiming Wang et al. · Journal of Clinical Oncology · 2020 · 197 citations

Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial

Binghe Xu, Qingyuan Zhang, Pin Zhang et al. · Nature Medicine · 2021 · 152 citations · Full text

Breast Oncology, Medicine, Pharmacology +7